title: [Effect of oral administration of β-D-glucan from Aureobasidium pullulans ADK-34 on Candida and MRSA infections in immunosuppressed mice].
abstract: We examined the effect of the oral administration of β-D-glucan derived from Aureobasidium pullulans ADK-34 (AP-FBG) on Candida albicans or methicillin-resistant Staphylococcus aureus (MRSA) infection in immunosuppressed mice. Mice pretreated with cyclophosphamide (CY) were intraperitoneally administered AP-FBG for 4 days and then infected with 6×10(4) C. albicans cells. In a preliminary experiment, the survival time of the Candida-infected mice treated with AP-FBG was clearly prolonged. Similarly, the effect of the oral administration of AP-FBG was examined. Mice were orally given 2.5% AP-FBG in feed for 42 days from 14 days prior to 2×10(4) C. albicans cells infection. The survival time of mice treated with AP-FBG was significantly prolonged and the viable cell count in the kidneys of the survivors was significantly decreased at 30 days after infection. The effects of the oral administration of AP-FBG on intestinal MRSA infection were also examined. Mice were given 2.5% AP-FBG orally in feed for 30 days before and after oral MRSA infection and treated with CY 12 days after the infection. The number of viable MRSA cells or the IgA production in feces did not significantly change, while AP-FBG administration seemed to relieve temporally the loss of body weight of mice.
  
  
  CONCLUSIONS
  These results suggest that oral pre-administration of AP-FBG promoted resistance of CY-treated mice to C. albicans and lessened the weight reduction of CY-mice infected by MRSA.
authors.affiliation: Life Science Department, Advanced Materials R&D Laboratory, ADEKA Corporation.
authors.forename: Asuka
authors.initials: A
authors.lastname: Tanioka
authors.forename: Kazumi
authors.initials: K
authors.lastname: Hayama
authors.forename: Masayasu
authors.initials: M
authors.lastname: Mitsuya
authors.forename: Shigeru
authors.initials: S
authors.lastname: Tansho
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Ono
authors.forename: Kazufumi
authors.initials: K
authors.lastname: Tsubaki
authors.forename: Shigeru
authors.initials: S
authors.lastname: Abe
mesh_terms: D000284:Administration, Oral; D000818:Animals; D001203:Ascomycota / Q000737:chemistry*; D002177:Candidiasis / Q000517:prevention & control*; D003520:Cyclophosphamide; D016867:Immunocompromised Host; D007165:Immunosuppression Therapy; D008020:Life Support Care; D055624:Methicillin-Resistant Staphylococcus aureus; D051379:Mice; D013203:Staphylococcal Infections / Q000517:prevention & control*; D015431:Weight Loss / Q000187:drug effects; D047071:beta-Glucans / Q000008:administration & dosage* / Q000302:isolation & purification / Q000494:pharmacology
chemical_list: D047071:beta-Glucans; D003520:Cyclophosphamide